These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20998816)

  • 21. [Antigenic and immunogenic properties of dry typhus exanthematosus vaccine].
    KARASEVA PS
    Zh Mikrobiol Epidemiol Immunobiol; 1954 Jul; 7():15-9. PubMed ID: 13196624
    [No Abstract]   [Full Text] [Related]  

  • 22. New type of vaccine from typhus lice.
    PSHENICHNOV AV; RAIKHER BI
    Am Rev Sov Med; 1947 Feb; 4(3):231-7. PubMed ID: 20285211
    [No Abstract]   [Full Text] [Related]  

  • 23. Typhus at Belsen. II. Clinical course of epidemic typhus in persons who had received Craigie typhus vaccine.
    DAVIS WA
    Ann Intern Med; 1951 Feb; 34(2):448-65. PubMed ID: 14800216
    [No Abstract]   [Full Text] [Related]  

  • 24. Studies on commercial typhus vaccines. II. The antigenic fractions of disrupted epidemic typhus rickettsiae.
    CHAMBERS LA; COHEN SS; CLAWSON JR
    J Immunol; 1950 Nov; 65(5):459-63. PubMed ID: 14794909
    [No Abstract]   [Full Text] [Related]  

  • 25. The quantitative estimation of egg and chicken proteins in equine encephalomyelitis vaccine.
    ENGEL LL; RANDALL R
    Fed Proc; 1947; 6(1):426. PubMed ID: 20343905
    [No Abstract]   [Full Text] [Related]  

  • 26. On increasing the yield and potency of typhus vaccine prepared from infected yolk sacs.
    GROUPE V; NIGG C; MACFARLANE JO
    J Immunol; 1946 Aug; 53():303-14. PubMed ID: 20998814
    [No Abstract]   [Full Text] [Related]  

  • 27. Antibody response of human subjects to epidemic typhus vaccine three to eight years after previous immunization.
    MURRAY ES; OFSTROCK A; SNYDER JC
    J Immunol; 1952 Feb; 68(2):207-18. PubMed ID: 14927925
    [No Abstract]   [Full Text] [Related]  

  • 28. [Pathomorphology of local reactions to typhus exanthematosus vaccine following sedimentation].
    GINDIN AP; IATSIMIRSKAIA-KRONTOVSKAIA MK; ZHIV BV; SALAGOVA TA
    Zh Mikrobiol Epidemiol Immunobiol; 1955 Jul; (7):69-71. PubMed ID: 13257798
    [No Abstract]   [Full Text] [Related]  

  • 29. Rickettsial vaccines with emphasis on epidemic typhus. Initial report of an old vaccine trial.
    Woodward TE
    S Afr Med J; 1986 Oct; Suppl():73-6. PubMed ID: 3095934
    [No Abstract]   [Full Text] [Related]  

  • 30. Active immunization against European typhus exanthematicus; efficacy of Durand's typhous vaccine in epidemiological experiments on men.
    KRIVISKY AS; KOMAROVA AF
    Zh Mikrobiol Epidemiol Immunobiol; 1945; (10):59-62. PubMed ID: 21027491
    [No Abstract]   [Full Text] [Related]  

  • 31. Epidemic typhus vaccine; antibody response to a single dose among persons previously vaccinated.
    GAULD RL; GOODNER K
    U S Armed Forces Med J; 1951 Sep; 2(9):1311-5. PubMed ID: 14867044
    [No Abstract]   [Full Text] [Related]  

  • 32. [Duration of efficacy of Rickettsial vaccine, formolized, and prepared by the Durand-Giroud method].
    HORRENBERGER R
    Arch Inst Pasteur Alger; 1950 Sep; 28(3):364-75. PubMed ID: 14800479
    [No Abstract]   [Full Text] [Related]  

  • 33. A method for increasing the infectivity of yolk-sac cultures of the rickettsiae of epidemic and murine typhus, and South African tick-bite fever.
    BERKOWITZ AP
    S Afr J Med Sci; 1946 Nov; 11(2-3):69-72. PubMed ID: 20282007
    [No Abstract]   [Full Text] [Related]  

  • 34. Dangers associated with the use of living attenuated typhus vaccine.
    SADUSK JF; KUHLENBECK H
    Am J Public Health Nations Health; 1946 Sep; 36():1027-30. PubMed ID: 20999373
    [No Abstract]   [Full Text] [Related]  

  • 35. The constitution of that rickettsia and soluble rickettsial antigen derived from the epidemic typhus vaccine.
    COHEN SS
    Fed Proc; 1946; 5(1 Pt 2):129. PubMed ID: 21066650
    [No Abstract]   [Full Text] [Related]  

  • 36. Studies on commercial typhus vaccines. III. The concentration and isolation of the Rickettsia-specific soluble antigen of commercial typhus vaccine.
    COHEN SS; CHAMBERS LA; CLAWSON JR
    J Immunol; 1950 Nov; 65(5):465-73. PubMed ID: 14794910
    [No Abstract]   [Full Text] [Related]  

  • 37. Methods of evaluation of typhus vaccine potency.
    MOSING H
    Tex Rep Biol Med; 1947; 5(2):173-6. PubMed ID: 20255935
    [No Abstract]   [Full Text] [Related]  

  • 38. Methods of evaluation of typhus vaccine potency.
    MOSING H
    Med Dent Bull; 1947 Nov; 19(11):104. PubMed ID: 20270896
    [No Abstract]   [Full Text] [Related]  

  • 39. The quantitative estimation of egg and chicken proteins in equine encephalomyelitis vaccines.
    ENGEL LL; RANDALL R
    J Immunol; 1947 Apr; 55(4):325-9. PubMed ID: 20294485
    [No Abstract]   [Full Text] [Related]  

  • 40. Serologic studies in typhus-vaccinated individuals; the effect of a stimulating dose of typhus vaccine on the Weil-Felix and complement-fixing antibodies.
    ZARAFONETIS CJ
    J Immunol; 1945 Nov; 51():365-74. PubMed ID: 21007105
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.